You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

32 Results
Drug
Other Name(s): Arimidex®
Oct 2024
Drug
Other Name(s): Zytiga®
Aug 2024
Regimen
Intent: Adjuvant
Funding:
ODB - General Benefit
    anastrozole
Apr 2024
Regimen
Cancer Type:
Breast, 
Gynecologic, 
Endometrial
Intent: Palliative
Funding:
ODB - General Benefit
    anastrozole
Apr 2024
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours, 
Sarcoma, 
GIST
Intent: Adjuvant
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Oct 2024
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours, 
Sarcoma, 
GIST
Intent: Palliative
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Oct 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Oct 2024
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Intent: Palliative
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Oct 2024
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
ODB - General Benefit
    abiraterone
ODB - General Benefit
    prednisone
Aug 2024
Regimen
Cancer Type:
Sarcoma, 
Ewing's
Intent: Palliative
Funding:
ODB - General Benefit
    temozolomide
Aug 2021
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Promyelocytic (APL)
Intent: Palliative, Curative
Funding:
ODB - General Benefit
    mercaptopurine
ODB - General Benefit
    methotrexate - oral tablets
Exceptional Access Program
    tretinoin (ATRA)
Jul 2021
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative
Funding:
New Drug Funding Program
    Calaspargase Pegol (Outpatient) - Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed_Biphenotypic Leukemia
New Drug Funding Program
    Pegaspargase (Outpatient) - Adult Acute Lymphoblastic Leukemia (ALL) Lymphoblastic Lymphoma Mixed or Biphenotypic Leukemia
ODB - General Benefit
    dexamethasone
Nov 2024

Pages